Alintegimod

DB18879InvestigationalSmall molecule

Alintegimod is under investigation in clinical trial NCT06362369 (A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy).

Mechanism: Pharmacologically active on Integrin alpha-L, Integrin beta-2, and VLA-4 (very late antigen-4)
Curator reviewed
Formula / weight: C₂₈H₃₂N₂O₆S₄ · 620.81 g/mol (avg)
Code names: 7HP-349

Resolves to

Compound

UNIINX38VST3GUCAS1378535-08-0

Structure

InChIKeyPSBCCRKKPBQYJK-UHFFFAOYSA-NSMILESO=C(OCCOCCOCCOC(=O)N(CC1=CC=CS1)CC1=CC=CS1)N(CC1=CC=CS1)CC1=CC=CS1

Targets

P20701ITGALP05107ITGB2

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Alintegimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account